JP2015506704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506704A5 JP2015506704A5 JP2014555799A JP2014555799A JP2015506704A5 JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5 JP 2014555799 A JP2014555799 A JP 2014555799A JP 2014555799 A JP2014555799 A JP 2014555799A JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant adenovirus
- nucleic acid
- adenovirus
- heterologous nucleic
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 56
- 230000002163 immunogen Effects 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 150000007523 nucleic acids Chemical group 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 11
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 10
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 10
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 10
- -1 IL13Rα Proteins 0.000 claims description 10
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 8
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 102000018697 Membrane Proteins Human genes 0.000 claims description 6
- 238000012737 microarray-based gene expression Methods 0.000 claims description 6
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 101150005585 E3 gene Proteins 0.000 claims description 4
- 241001135569 Human adenovirus 5 Species 0.000 claims description 4
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- APHFXDBDLKPMTA-UHFFFAOYSA-N 2-(3-decanoyl-4,5,7-trihydroxynaphthalen-2-yl)acetic acid Chemical compound CCCCCCCCCC(=O)c1c(CC(O)=O)cc2cc(O)cc(O)c2c1O APHFXDBDLKPMTA-UHFFFAOYSA-N 0.000 claims description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 102100027106 BRCA1-associated protein Human genes 0.000 claims description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims description 2
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims description 2
- 108060000903 Beta-catenin Proteins 0.000 claims description 2
- 102000015735 Beta-catenin Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101150104494 CAV1 gene Proteins 0.000 claims description 2
- 101150012716 CDK1 gene Proteins 0.000 claims description 2
- 102000000905 Cadherin Human genes 0.000 claims description 2
- 108050007957 Cadherin Proteins 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims description 2
- 108090000538 Caspase-8 Proteins 0.000 claims description 2
- 102000004225 Cathepsin B Human genes 0.000 claims description 2
- 108090000712 Cathepsin B Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100038281 Cytospin-A Human genes 0.000 claims description 2
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 claims description 2
- 102100024400 Diphthine methyltransferase Human genes 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims description 2
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims description 2
- 102100039717 G antigen 1 Human genes 0.000 claims description 2
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 102100034153 Golgin subfamily A member 6B Human genes 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 claims description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 101000984746 Homo sapiens BRCA1-associated protein Proteins 0.000 claims description 2
- 101000944524 Homo sapiens Bombesin receptor-activated protein C6orf89 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000884816 Homo sapiens Cytospin-A Proteins 0.000 claims description 2
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 claims description 2
- 101001053233 Homo sapiens Diphthine methyltransferase Proteins 0.000 claims description 2
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 claims description 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims description 2
- 101100449143 Homo sapiens GOLGA6B gene Proteins 0.000 claims description 2
- 101000981252 Homo sapiens GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 101000866478 Homo sapiens Heat shock protein 105 kDa Proteins 0.000 claims description 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 2
- 101001001418 Homo sapiens Inhibitor of growth protein 4 Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000979578 Homo sapiens NK-tumor recognition protein Proteins 0.000 claims description 2
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 claims description 2
- 101100029612 Homo sapiens PHF20 gene Proteins 0.000 claims description 2
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 claims description 2
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101000583459 Homo sapiens Progesterone-induced-blocking factor 1 Proteins 0.000 claims description 2
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 claims description 2
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 claims description 2
- 101000849300 Homo sapiens Ribosomal RNA processing protein 36 homolog Proteins 0.000 claims description 2
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims description 2
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 claims description 2
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 claims description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 2
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 claims description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims description 2
- 101000823796 Homo sapiens Y-box-binding protein 1 Proteins 0.000 claims description 2
- 102100035677 Inhibitor of growth protein 4 Human genes 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102000016776 Midkine Human genes 0.000 claims description 2
- 108010092801 Midkine Proteins 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 2
- 102100023384 NK-tumor recognition protein Human genes 0.000 claims description 2
- 102000008730 Nestin Human genes 0.000 claims description 2
- 108010088225 Nestin Proteins 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 102100033615 Nucleoprotein TPR Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 102100036878 PHD finger protein 20 Human genes 0.000 claims description 2
- 101150038998 PLAUR gene Proteins 0.000 claims description 2
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 2
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 claims description 2
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 2
- 102100031015 Progesterone-induced-blocking factor 1 Human genes 0.000 claims description 2
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 102100029831 Reticulon-4 Human genes 0.000 claims description 2
- 102100033981 Ribosomal RNA processing protein 36 homolog Human genes 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 2
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 101150006914 TRP1 gene Proteins 0.000 claims description 2
- 102100038808 Transcription factor SOX-10 Human genes 0.000 claims description 2
- 102100022415 Transcription factor SOX-11 Human genes 0.000 claims description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 2
- 102100039094 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims description 2
- 102100022224 Y-box-binding protein 1 Human genes 0.000 claims description 2
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 108010066416 multidrug resistance-associated protein 3 Proteins 0.000 claims description 2
- 210000005055 nestin Anatomy 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims description 2
- 108010014186 ras Proteins Proteins 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594005P | 2012-02-02 | 2012-02-02 | |
| US61/594,005 | 2012-02-02 | ||
| PCT/US2013/024506 WO2013116778A2 (en) | 2012-02-02 | 2013-02-01 | Immunogenic adenovirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Division JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506704A JP2015506704A (ja) | 2015-03-05 |
| JP2015506704A5 true JP2015506704A5 (OSRAM) | 2016-03-17 |
| JP6325459B2 JP6325459B2 (ja) | 2018-05-16 |
Family
ID=47714593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555799A Active JP6325459B2 (ja) | 2012-02-02 | 2013-02-01 | 腫瘍関連異種抗原を発現するアデノウイルス |
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11155599B2 (OSRAM) |
| EP (1) | EP2809788B1 (OSRAM) |
| JP (2) | JP6325459B2 (OSRAM) |
| KR (1) | KR102100092B1 (OSRAM) |
| CN (2) | CN110042086A (OSRAM) |
| AU (1) | AU2013214776B2 (OSRAM) |
| BR (1) | BR112014019049A2 (OSRAM) |
| CA (1) | CA2863523A1 (OSRAM) |
| DK (1) | DK2809788T3 (OSRAM) |
| ES (1) | ES2759785T3 (OSRAM) |
| NZ (1) | NZ628213A (OSRAM) |
| SG (3) | SG11201404495RA (OSRAM) |
| WO (1) | WO2013116778A2 (OSRAM) |
| ZA (1) | ZA201405755B (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| CA2931322A1 (en) * | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| CN104328140B (zh) * | 2014-10-08 | 2018-06-05 | 兰州大学 | 一种高嗜性膀胱癌靶向性肿瘤杀伤腺病毒 |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| KR20170102002A (ko) | 2015-01-09 | 2017-09-06 | 이투빅스 코포레이션 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
| CN104762269A (zh) * | 2015-03-18 | 2015-07-08 | 红土生物技术有限公司 | 一种增强肿瘤抗原免疫原性的新策略及其在肺癌免疫治疗中的应用 |
| WO2016172249A1 (en) * | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US11000560B2 (en) | 2015-05-04 | 2021-05-11 | Vcn Biosciences, S.L. | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
| CN105087648B (zh) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 |
| CN105087647B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| WO2017112797A1 (en) | 2015-12-22 | 2017-06-29 | Thomas Jefferson University | Intra-lesional cmv-based cancer vaccines |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| CN105779480B (zh) * | 2016-03-24 | 2020-03-20 | 成都康景生物科技有限公司 | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 |
| DK3436591T5 (da) * | 2016-03-31 | 2024-09-16 | The European Molecular Biology Laboratory | Adenovirale coat-protein-afledte transportvehikler |
| EP3463405A4 (en) * | 2016-05-27 | 2020-02-26 | DNAtrix, Inc. | ADENOVIRUS AND IMMUNO MODULATOR COMBINATION THERAPY |
| JP2019536468A (ja) | 2016-12-12 | 2019-12-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍を標的にする合成アデノウイルスおよびその使用 |
| WO2018118967A1 (en) | 2016-12-21 | 2018-06-28 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
| KR20190128634A (ko) * | 2017-01-30 | 2019-11-18 | 에피센트알엑스, 인코포레이티드 | 다중 트랜스진 재조합 아데노바이러스 |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| EP3714038A1 (en) | 2017-11-22 | 2020-09-30 | Mesoblast International Sàrl | Cellular compositions and methods of treatment i |
| GB201804468D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| WO2019237371A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 定点插入 ct1.1 基因的 cho 细胞株的构建方法及其用途 |
| CN109081873B (zh) * | 2018-08-10 | 2022-04-22 | 固安鼎泰海规生物科技有限公司 | 一种抗肿瘤重组nmm融合抗原质粒dna疫苗 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020259189A1 (zh) * | 2019-06-27 | 2020-12-30 | 北京太东生物科技有限公司 | Sox11作为精神分裂症诊断标记物的应用 |
| CA3149478A1 (en) | 2019-08-05 | 2021-02-11 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| PH12022551208A1 (en) | 2019-11-18 | 2023-04-24 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| KR102601875B1 (ko) * | 2020-03-25 | 2023-11-14 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN111850041A (zh) * | 2020-07-30 | 2020-10-30 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的含il12双顺反子的病毒构建体及其用途和构建方法 |
| EP4192940A1 (en) | 2020-08-10 | 2023-06-14 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
| JP2025536260A (ja) | 2022-10-11 | 2025-11-05 | イェール ユニバーシティー | 細胞透過性抗体の組成物および使用方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| AU716045B2 (en) | 1994-11-28 | 2000-02-17 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| DE69628744D1 (de) | 1995-04-17 | 2003-07-24 | Univ Texas System Austin Board | Adenovirus helfervirus system |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| WO1998039467A2 (en) | 1997-03-03 | 1998-09-11 | Calydon, Inc. | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof |
| US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| CA2351587A1 (en) | 1998-11-18 | 2000-05-25 | Canji, Inc. | Viral vectors with late transgene expression |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| AU767904B2 (en) | 1999-05-12 | 2003-11-27 | Uab Research Foundation, The | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| AU1190901A (en) | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| EP1223947A4 (en) | 1999-10-15 | 2004-12-08 | Canji Inc | TARGETED VECTORS |
| US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| US20030211477A1 (en) * | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| CN104059147A (zh) | 2003-06-27 | 2014-09-24 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| US20070134202A1 (en) | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2407177A1 (en) * | 2010-07-13 | 2012-01-18 | Institut Gustave Roussy | Adenovirus vaccine vectors |
| EP2383577A1 (en) | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| WO2011140284A2 (en) * | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| AU2014281826B2 (en) | 2013-06-18 | 2019-10-17 | Board Of Regents, The University Of Texas System | Treatment of brain cancer with oncolytic adenovirus |
-
2013
- 2013-02-01 US US14/375,842 patent/US11155599B2/en active Active
- 2013-02-01 JP JP2014555799A patent/JP6325459B2/ja active Active
- 2013-02-01 BR BR112014019049A patent/BR112014019049A2/pt not_active Application Discontinuation
- 2013-02-01 SG SG11201404495RA patent/SG11201404495RA/en unknown
- 2013-02-01 EP EP13704334.5A patent/EP2809788B1/en active Active
- 2013-02-01 WO PCT/US2013/024506 patent/WO2013116778A2/en not_active Ceased
- 2013-02-01 ES ES13704334T patent/ES2759785T3/es active Active
- 2013-02-01 CN CN201910116066.XA patent/CN110042086A/zh active Pending
- 2013-02-01 CN CN201380017639.4A patent/CN104271748B9/zh not_active Expired - Fee Related
- 2013-02-01 KR KR1020147024570A patent/KR102100092B1/ko not_active Expired - Fee Related
- 2013-02-01 SG SG10201913795TA patent/SG10201913795TA/en unknown
- 2013-02-01 SG SG10201606356YA patent/SG10201606356YA/en unknown
- 2013-02-01 NZ NZ628213A patent/NZ628213A/en not_active IP Right Cessation
- 2013-02-01 AU AU2013214776A patent/AU2013214776B2/en not_active Ceased
- 2013-02-01 DK DK13704334T patent/DK2809788T3/da active
- 2013-02-01 CA CA2863523A patent/CA2863523A1/en not_active Abandoned
-
2014
- 2014-08-05 ZA ZA2014/05755A patent/ZA201405755B/en unknown
-
2018
- 2018-04-12 JP JP2018076878A patent/JP2018138033A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506704A5 (OSRAM) | ||
| JP2018519847A5 (OSRAM) | ||
| ES2759785T3 (es) | Adenovirus que expresan antígenos oncógenos heterólogos | |
| Vici et al. | Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies | |
| De Haan et al. | Viral gene delivery vectors: the next generation medicines for immune-related diseases | |
| Gil et al. | CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells | |
| Anderson et al. | Plasmid DNA and viral vector-based vaccines for the treatment of cancer | |
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| JP2016540505A5 (OSRAM) | ||
| Kim et al. | Poxviral vectors for cancer immunotherapy | |
| JP2025160281A (ja) | 個別化ワクチン | |
| Asad et al. | Viral gene therapy for breast cancer: progress and challenges | |
| Liu et al. | An oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation | |
| JP2017501695A5 (OSRAM) | ||
| Biegert et al. | Current development in adenoviral vectors for cancer immunotherapy | |
| Goyvaerts et al. | The journey of in vivo virus engineered dendritic cells from bench to bedside: a bumpy road | |
| Chaurasiya et al. | Viroimmunotherapy for breast cancer: Promises, problems and future directions | |
| Kim et al. | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| Lundstrom | Alphaviruses in cancer therapy | |
| Osada et al. | Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| Guo et al. | Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model | |
| White et al. | Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer |